ライフサイエンスコーパス: isavuconazole

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 everal azoles but higher susceptibilities to isavuconazole.

2 Patients were given isavuconazole 200 mg (as its intravenous or oral water-s

3 1 mug/ml), posaconazole (0.5 and 1 mug/ml), isavuconazole (4 and 4 mug/ml), and amphotericin B (0.25

4 o day 42 for the ITT population was 19% with isavuconazole (48 patients) and 20% with voriconazole (5

5 The activities of isavuconazole against the larger collection of Candida s

6 We report the MIC distributions for isavuconazole and 111 isolates of Candida (42 Candida al

7 ere reported in 109 (42%) patients receiving isavuconazole and 155 (60%) receiving voriconazole (p<0.

8 Most patients (247 [96%] receiving isavuconazole and 255 [98%] receiving voriconazole) had

9 Mucormycosis cases treated with isavuconazole as primary treatment were matched with con

10 Isavuconazole can be used for treatment of mucormycosis

11 ality in seven (33%) of 21 primary-treatment isavuconazole cases was similar to 13 (39%) of 33 amphot

12 Isavuconazole demonstrates broad-spectrum activity again

13 2013, 37 patients with mucormycosis received isavuconazole for a median of 84 days (IQR 19-179, range

14 mphotericin, he was treated effectively with isavuconazole for over 6 months despite ongoing treatmen

15 Our results support the use of isavuconazole for the primary treatment of patients with

16 We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared

17 ulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1

18 Isavuconazole is a new broad-spectrum triazole with a fa

19 Isavuconazole is a new extended-spectrum triazole with a

20 Isavuconazole is a novel triazole with broad-spectrum an

21 Isavuconazole is a triazole active in vitro and in anima

22 Isavuconazole is an extended-spectrum triazole with in v

23 Isavuconazole (ISAV) is a novel, broad-spectrum, triazol

24 Also, the relative activities of isavuconazole, itraconazole, fluconazole, posaconazole,

25 Isavuconazole MIC values for three mucormycete isolates

26 e study included 158 patients overall and 78 isavuconazole patients in the PK/PD modeling.

27 acodynamic (PK/PD) analysis in patients with isavuconazole plasma concentrations was conducted to est

28 azole and voriconazole; the MIC90 values for isavuconazole, posaconazole, and voriconazole against Ca

29 Isavuconazole showed activity against mucormycosis with

30 Isavuconazole showed good activities against Cryptococcu

31 f invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amph

32 ed to result in a negative GMI at the end of isavuconazole therapy.

33 However, isavuconazole-treated patients had a lower frequency of

34 SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invas

35 Isavuconazole was non-inferior to voriconazole for the p

36 ive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole.

37 Isavuconazole was well tolerated compared with voriconaz

38 se studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few s

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。